Curemeta
- Biotech or pharma, therapeutic R&D
CureMeta is a Boston-based Biotech developing new Antibody and Antibody-Drug-Conjugate (ADC) therapeutics to treat and cure patients suffering from solid tumor and metastatic disease. We utilize a novel and proprietary antibody discovery platform to develop antibodies and ADCs to embryonic cancer targets found in metastatic and aggressive solid tumors. Our lead ADC is CM-14 for patients with metastatic pancreatic and gastric cancers. CureMeta is currently undergoing the transition from a preclinical to a clinical biotech and preparations are underway to take CM-14 into a human clinical cancer trial. We are raising a financing round and seek investors and pharma partnerships to advance this First-in-Class ADC to the clinic in first-in-human studies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}